CAS 867160-71-2
:Linsitinib
Description:
Linsitinib, with the CAS number 867160-71-2, is a small molecule inhibitor primarily targeting the insulin-like growth factor 1 receptor (IGF-1R) and the insulin receptor (IR). It is classified as a tyrosine kinase inhibitor and is notable for its potential therapeutic applications in oncology, particularly in the treatment of various cancers, including those resistant to conventional therapies. Linsitinib exhibits a unique mechanism of action by disrupting the signaling pathways associated with cell proliferation and survival, which are often upregulated in cancerous cells. The compound is typically administered orally and has been evaluated in clinical trials for its efficacy and safety profile. In terms of its chemical structure, Linsitinib contains multiple functional groups that contribute to its biological activity and solubility characteristics. As with many pharmaceutical agents, its pharmacokinetics, including absorption, distribution, metabolism, and excretion, are critical for determining its therapeutic potential and dosing regimens. Overall, Linsitinib represents a significant advancement in targeted cancer therapies.
Formula:C26H23N5O
InChI:InChI=1/C26H23N5O/c1-26(32)14-19(15-26)25-30-22(23-24(27)28-11-12-31(23)25)18-8-7-17-9-10-20(29-21(17)13-18)16-5-3-2-4-6-16/h2-13,19,32H,14-15H2,1H3,(H2,27,28)/t19-,26+
InChI key:InChIKey=PKCDDUHJAFVJJB-VLZXCDOPNA-N
SMILES:NC=1C=2N(C(=NC2C3=CC4=C(C=C3)C=CC(=N4)C5=CC=CC=C5)[C@H]6C[C@@](C)(O)C6)C=CN1
Synonyms:- Cyclobutanol, 3-[8-amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methyl-, cis-
- Linsitinib
- Osi 906Aa
- Osi-906
- cis-3-[8-Amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutanol
- cis-3-[8-Amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutanol Linsitinib(OSI906)
- 3-(8-Amino-1-(2-phenylquinolin-7-yl)-2,3-dihydro-imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobuta
- Linsitinib(OSI906)
- Linsitinib, Free Base
- (1S,3r)-3-((S)-8-aMino-1-(2-phenylquinolin-7-yl)-2,3-dihydroiMidazo[1,5-a]pyrazin-3-yl)-1-Methylcyclobutanol
- (1s,3r)-3-[4-aMino-3-(2-phenylquinolin-7-yl)iMidazo[1,5-a]pyrazin-1-yl]-1-Methylcyclobutan-1-ol
- (1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol
- See more synonyms
Filter by
Purity percentage
0
100
|
0
|
50
|
90
|
95
|
100
Found 8 products.
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
Cis-3-(8-Amino-1-(2-Phenylquinolin-7-Yl)Imidazo[1,5-A]Pyrazin-3-Yl)-1-Methylcyclobutan-1-Ol
CAS:Cis-3-(8-Amino-1-(2-Phenylquinolin-7-Yl)Imidazo[1,5-A]Pyrazin-3-Yl)-1-Methylcyclobutan-1-OlFormula:C26H23N5OPurity:98%Molecular weight:421.49Linsitinib
CAS:Controlled ProductApplications Linsitinib is a small-molecule dual insulin-like growth factor-1 receptor (IGF-IR) and insulin receptor (IR) kinase inhibitor. IGF-I receptor (IGF-IR) has been implicated in the promotion of tumorigenesis, metastasis and resistance to cancer therapies and thus Linsitinib may be a useful anticancer agent. Potent IGF-1R inhibitor.
References Mulvihill, M.M.J. et al.: Fut. Med. Chem., 1, 1153 (2009); Flanigan, S.A. et al.: Clin. Cancer Res., 16, 5436 (2010); McKinley, E.T. et al.: Clin. Cancer Res., 17, 3332 (2011);Formula:C26H23N5OColor and Shape:NeatMolecular weight:421.49Linsitinib
CAS:Cis-3-(8-Amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutan-1-olFormula:C26H23N5OPurity:98%Molecular weight:421.49Linsitinib
CAS:OSI-906 (Linsitinib) is an oral inhibitor of IGF-1R with anti-cancer properties, potentially halting tumor growth and inducing cell death.Formula:C26H23N5OPurity:98.31% - ≥95%Color and Shape:SolidMolecular weight:421.49
